The Japanese Society of Hypertension (JSH) revised the Guidelines for the Management of
Hypertension 2014 (JSH 2014), and published the JSH 2019. In the development of the JSH …

Arterial hypertension is the most important contributor to the global burden of disease;
however, disease control remains poor. Although the diagnosis of hypertension is still based …

Background Endovascular renal denervation reduces blood pressure in patients with mild-to-
moderate hypertension, but its efficacy in patients with true resistant hypertension has not …

Background Renal denervation has been shown to lower blood pressure in the presence of
antihypertensive medications; however, long-term safety and efficacy data from randomised …

Background Catheter-based renal denervation has significantly reduced blood pressure in
previous studies. Following a positive pilot trial, the SPYRAL HTN-OFF MED (SPYRAL …

Excessive adiposity raises blood pressure and accounts for 65–75% of primary
hypertension, which is a major driver of cardiovascular and kidney diseases. In obesity …

Summary Background The SYMPLICITY HTN-3 (Renal Denervation in Patients With
Uncontrolled Hypertension) trial showed the safety but not efficacy of the Symplicity system …

Since the publication of the 2018 European Society of Cardiology/European Society of
Hypertension (ESC/ESH) Guidelines for the Management of Arterial Hypertension, several …

Importance Two initial sham-controlled trials demonstrated that ultrasound renal denervation
decreases blood pressure (BP) in patients with mild to moderate hypertension and …

Aims Several studies and registries have demonstrated sustained reductions in blood
pressure (BP) after renal denervation (RDN). The long-term safety and efficacy after RDN in …